Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 4/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 13/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 12/20 | 0.59 |
| ▸ | ADRA2B | P18089 | 12/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.59 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | HRH2 | P25021 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11769742 | 0.98 | HTR1D (0.62) | HTR1DADRA2CADRA2AADRA2BADRA1A | |
| SCHEMBL4761139 | 0.91 | HTR1D (0.75) | HTR1DADRA2CADRA2AADRA2BADRA1A | |
| SCHEMBL9069376 | 0.82 | CFB (0.51) | HTR1DADRA2CADRA2AADRA2BADRA1A | |
| SCHEMBL9070164 | 0.81 | HTR1D (0.56) | HTR1DADRA2CADRA2AADRA2BADRA1A | |
| SCHEMBL29374579 | 0.78 | ADRA2C (0.65) | HTR1DADRA2CADRA2AADRA2BADRA1A | |
| SCHEMBL4760243 | 0.78 | HTR1D (1.00) | HTR1DADRA2CADRA2AADRA2BADRA1A | |
| SCHEMBL11218999 | 0.78 | TAAR1 (0.50) | HTR1DADRA2CADRA2AADRA2BADRA1A | |
| Clonidine SCHEMBL18050245 | 0.77 | ADRA2A (0.82) | HTR1DADRA2CADRA2AADRA2BADRA1A | |
| Hydrochloric Acid SCHEMBL29384552 | 0.77 | HTR1D (0.97) | HTR1DADRA2CADRA2AADRA2BADRA1A | |
| SCHEMBL7087068 | 0.77 | HTR1D (0.45) | HTR1DADRA2CADRA2AADRA2BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230404979-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS TO REDUCE MORTALITY AND IMPROVE OUTCOMES IN VIRAL RESPIRATORY SYNDROMES | RUSH UNIVERSITY MEDICAL CENTER (US) | 2023-12-21 | — | — | US | claimed |
| CN-116004627-A | miRNA, method for detecting and regulating secondary growth rate of mangrove plants, detection kit and application of detection kit | 广东海洋大学 | 2023-04-25 | — | — | CN | claimed |
| EP-4031000-A1 | SYSTEMS AND METHODS FOR DETECTION AND PREVENTION OF EMERGENCE OF AGITATION | Bioxcel Therapeutics, Inc. (US) | 2022-07-27 | — | — | EP | claimed |
| US-20220202373-A1 | SYSTEMS AND METHODS OF USING MACHINE LEARNING TO DETECT AND PREDICT EMERGENCE OF AGITATION BASED ON SYMPATHETIC NERVOUS SYSTEM ACTIVITIES | BIOXCEL THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | US | claimed |
| CN-114667095-A | System and method for detecting and preventing irritability occurrences | 比奥克斯塞尔医疗股份有限公司 | 2022-06-24 | — | — | CN | claimed |
| WO-2022093767-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS TO REDUCE MORTALITY AND IMPROVE OUTCOMES IN VIRAL RESPIRATORY SYNDROMES | RUSH UNIVERSITY MEDICAL CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| CN-101370500-A | Use of 2-imidazoles for the treatment of CNS disorders | HOFFMANN LA ROCHE (CH) | 2009-02-18 | — | — | CN | claimed |
| EP-1981498-A2 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-la Roche AG (CH) | 2008-10-22 | — | — | EP | claimed |
| US-20070197569-A1 | Method for treating central nervous system disorders with substituted 2-imidazoline derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | claimed |
| WO-2007090720-A2 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | claimed |
| EP-0086428-B1 | ANTIDIARRHOEA VETERINARY COMPOSITION, ITS PRODUCTION AND ORAL DOSER CONTAINING IT | BEECHAM GROUP PLC (GB) | 1987-07-29 | — | — | EP | claimed |
| EP-0025269-B1 | ANTI-DIARRHOEA VETERINARY COMPOSITION | BEECHAM GROUP PLC (GB) | 1985-11-13 | — | — | EP | claimed |
| US-3969525-A | 2-(2',6'-DIETHYLPHENYL-AMINO)-1,3-DIAZACYCLOPENTENE(2) | BOEHRINGER INGELHEIM GMBH (DT) | 1976-07-13 | — | — | US | claimed |
| CN-122091550-A | High-performance lithium ion battery anode material Si@void@C@NC and preparation method thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122055137-A | Nanoparticles and formulations thereof for delivery of therapeutic agents throughout the central nervous system | 伊莱利利公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122010746-A | Method for preparing aromatic amide by heterogeneous reductive amidation of nitroaromatic hydrocarbon | 中国科学院大连化学物理研究所 | 2026-05-12 | — | — | CN | disclosed |
| WO-1989011851-A1 | TREATMENT OF INFLAMMATORY DISEASES, IN PARTICULAR RHEUMATOID ARTHRITIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1989-12-14 | — | — | WO | disclosed |
| US-4025607-A | ANALGESICS, HYPOTENSIVES | BOEHRINGER INGELHEIM GMBH (DT) | 1977-05-24 | — | — | US | disclosed |
| US-3969525-A | 2-(2',6'-DIETHYLPHENYL-AMINO)-1,3-DIAZACYCLOPENTENE(2) | BOEHRINGER INGELHEIM GMBH (DT) | 1976-07-13 | — | — | US | disclosed |
| US-3969525-A | 2-(2',6'-DIETHYLPHENYL-AMINO)-1,3-DIAZACYCLOPENTENE(2) | BOEHRINGER INGELHEIM GMBH (DT) | 1976-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197569-A1 | Method for treating central nervous system disorders with substituted 2-imidazoline derivatives | CRY1, HTR2C, PER2 | HTR1D 52/4885ADRA2C 15/4885ADRA2A 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.